BR112023022851A2 - PEPTIDE 1 RECEPTOR AGONISTS SIMILAR TO MACROCYCLIC GLUCAGON - Google Patents
PEPTIDE 1 RECEPTOR AGONISTS SIMILAR TO MACROCYCLIC GLUCAGONInfo
- Publication number
- BR112023022851A2 BR112023022851A2 BR112023022851A BR112023022851A BR112023022851A2 BR 112023022851 A2 BR112023022851 A2 BR 112023022851A2 BR 112023022851 A BR112023022851 A BR 112023022851A BR 112023022851 A BR112023022851 A BR 112023022851A BR 112023022851 A2 BR112023022851 A2 BR 112023022851A2
- Authority
- BR
- Brazil
- Prior art keywords
- macrocyclic
- glucagon
- peptide
- receptor agonists
- similar
- Prior art date
Links
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 title 1
- 102000051325 Glucagon Human genes 0.000 title 1
- 108060003199 Glucagon Proteins 0.000 title 1
- 101710176384 Peptide 1 Proteins 0.000 title 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 229960004666 glucagon Drugs 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Abstract
agonistas de receptor de peptídeo 1 similares ao glucagon macrocíclico. a presente invenção refere-se em uma modalidade, a um composto da fórmula ou um sal farmaceuticamente aceitável do mesmo, e métodos de uso deste composto para tratar diabetes mellitus tipo ii.macrocyclic glucagon-like peptide-1 receptor agonists. The present invention relates, in one embodiment, to a compound of the formula or a pharmaceutically acceptable salt thereof, and methods of using this compound to treat type II diabetes mellitus.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191034P | 2021-05-20 | 2021-05-20 | |
| US202163254564P | 2021-10-12 | 2021-10-12 | |
| EP21383172 | 2021-12-21 | ||
| PCT/US2022/029958 WO2022246019A1 (en) | 2021-05-20 | 2022-05-19 | Macrocyclic glucagon-like peptide 1 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022851A2 true BR112023022851A2 (en) | 2024-01-23 |
Family
ID=82016585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022851A BR112023022851A2 (en) | 2021-05-20 | 2022-05-19 | PEPTIDE 1 RECEPTOR AGONISTS SIMILAR TO MACROCYCLIC GLUCAGON |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4341255A1 (en) |
| KR (1) | KR20230173166A (en) |
| AU (1) | AU2022275931A1 (en) |
| BR (1) | BR112023022851A2 (en) |
| CA (1) | CA3218345A1 (en) |
| IL (1) | IL308397A (en) |
| TW (1) | TW202310838A (en) |
| WO (1) | WO2022246019A1 (en) |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3555064T5 (en) | 2016-12-16 | 2023-05-01 | Pfizer | GLP-1 receptor agonists and uses thereof |
| TWI707683B (en) | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Glp-1 receptor agonists and uses thereof |
| BR112020024956A2 (en) | 2018-06-15 | 2021-03-09 | Pfizer Inc. | GLP-1 RECEPTOR AGONISTS AND USES OF THE SAME |
| EP3883928A4 (en) | 2018-11-22 | 2022-06-29 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| CR20210562A (en) | 2019-04-12 | 2022-02-18 | Qilu Regor Therapeutics Inc | Glp-1r agonists and uses thereof |
| TWI751585B (en) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | Glucagon-like peptide 1 receptor agonists |
| WO2021018023A1 (en) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | Small molecule glp-1 receptor modulator |
| AU2020369568B2 (en) | 2019-10-25 | 2024-03-21 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| CN114728939B (en) | 2019-11-15 | 2023-12-08 | 日东制药株式会社 | GLP-1 receptor agonists and uses thereof |
| US20230051318A1 (en) | 2019-12-02 | 2023-02-16 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| CN115335374A (en) | 2020-01-29 | 2022-11-11 | 吉利德科学公司 | GLP-1R modulating compounds |
| WO2021160127A1 (en) | 2020-02-13 | 2021-08-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| IL296336A (en) | 2020-03-18 | 2022-11-01 | Lg Chemical Ltd | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| TW202144340A (en) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Fused imidazole derivatives, preparation method and medical use thereof |
| US20230295154A1 (en) | 2020-04-29 | 2023-09-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| KR102588241B1 (en) | 2020-06-04 | 2023-10-11 | 항저우 사이윈드 바이오사이언시즈 컴퍼니 리미티드 | Five-membered heteroaromatic imidazole compounds and uses thereof |
| US20230234968A1 (en) | 2020-06-10 | 2023-07-27 | Medshine Discovery Inc. | Methyl-substituted benzobisoxazole compound and use thereof |
| CN113801136B (en) | 2020-06-16 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | Imidazo heteroaryl derivative, preparation method and application thereof in medicine |
| CN115916772A (en) | 2020-06-19 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 6-oxo-3, 6-dihydropyridine derivatives, preparation method and application thereof in medicines |
| WO2021259309A1 (en) | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1 receptor agonist, and pharmaceutical composition and use thereof |
| CA3190163A1 (en) | 2020-08-06 | 2022-02-10 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2022031994A1 (en) | 2020-08-06 | 2022-02-10 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| US20220089578A1 (en) | 2020-08-21 | 2022-03-24 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| WO2022042691A1 (en) | 2020-08-28 | 2022-03-03 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20230322756A1 (en) | 2020-09-01 | 2023-10-12 | Jiangsu Hengrui Medicine Co., Ltd. | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| CN115515956A (en) | 2020-09-29 | 2022-12-23 | 深圳信立泰药业股份有限公司 | Benzimidazole derivative and preparation method and medical application thereof |
| WO2022078152A1 (en) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | Benzimidazolone glp-1 receptor agonist and use thereof |
| CN116547279A (en) | 2020-10-13 | 2023-08-04 | 加舒布鲁姆生物公司 | Heterocyclic GLP-1 agonists |
| EP4229049A1 (en) | 2020-10-13 | 2023-08-23 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN113480534B (en) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | Benzimidazole or azabenzimidazole-6-carboxylic acid compounds and application thereof |
-
2022
- 2022-05-17 TW TW111118381A patent/TW202310838A/en unknown
- 2022-05-19 CA CA3218345A patent/CA3218345A1/en active Pending
- 2022-05-19 KR KR1020237039778A patent/KR20230173166A/en active Search and Examination
- 2022-05-19 IL IL308397A patent/IL308397A/en unknown
- 2022-05-19 BR BR112023022851A patent/BR112023022851A2/en unknown
- 2022-05-19 WO PCT/US2022/029958 patent/WO2022246019A1/en active Application Filing
- 2022-05-19 AU AU2022275931A patent/AU2022275931A1/en active Pending
- 2022-05-19 EP EP22729392.5A patent/EP4341255A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202310838A (en) | 2023-03-16 |
| KR20230173166A (en) | 2023-12-26 |
| EP4341255A1 (en) | 2024-03-27 |
| WO2022246019A1 (en) | 2022-11-24 |
| AU2022275931A1 (en) | 2023-11-02 |
| IL308397A (en) | 2024-01-01 |
| CA3218345A1 (en) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021023923A2 (en) | Glucagon-like peptide 1 receptor agonists | |
| PE20170954A1 (en) | GIP AND GLP-1 CO-AGONIST COMPOUNDS | |
| CL2021000158A1 (en) | Gip / glp1 coagonist compounds | |
| BR112019010624A2 (en) | double acylated glp-1 / glp-2 agonists and composition | |
| PE20120206A1 (en) | ACTIVIN IIB RECEPTOR POLYPEPTIDE VARIANTS | |
| EA201370099A1 (en) | THERAPY ON THE BASIS OF LIGANDS OF CHEMOSENSOR RECEPTORS | |
| AR099975A1 (en) | DERIVATIVES OF EXENDINA-4 AS DUAL PEPTIDE AGONISTS OF THE GLP-1 / GLUCAGÓN RECEPTOR | |
| AR081200A1 (en) | INSULIN FORMULATIONS OF PROLONGED ACTION | |
| EP2070946A3 (en) | Invention affecting GLP-1 and Exendin | |
| BR112021020071A2 (en) | Dual agonist compounds of the glp-1 and gip receptor and their use | |
| CL2010000667A1 (en) | Compounds derived from cyclohexyl-piperazinyl-methanone, antagonists and / or inverse agonists h3; preparation procedure; pharmaceutical composition; and use of the compound for the treatment of obesity, type II diabetes and dyslipidemia (sol. div. 60-07). | |
| PE20220938A1 (en) | GIPR AGONIST COMPOUNDS | |
| PE20211417A1 (en) | NEW GLP-1 ANALOGS | |
| EA202191379A1 (en) | COMBINED NAFLD AND NASH TREATMENT | |
| BR112023003668A2 (en) | DUAL GLP-1/GIP AGONISTS | |
| MX2022009149A (en) | Gip/glp1 co-agonist compounds. | |
| NO20080552L (en) | GLP-1 Pharmaceutical Compositions | |
| EP4272823A3 (en) | Pharmaceutical composition for treating sarcopenia comprising glucagon-like peptide-1 receptor agonist | |
| BR112023022851A2 (en) | PEPTIDE 1 RECEPTOR AGONISTS SIMILAR TO MACROCYCLIC GLUCAGON | |
| BR112022024680A2 (en) | CONJUGATED MOLECULE, PHARMACEUTICAL COMPOSITION, METHOD FOR REDUCE BODY WEIGHT OF A MAMMAL, AND NON-THERAPEUTIC TREATMENT OF MAMMALS TO REDUCE BODY WEIGHT | |
| JOP20220153A1 (en) | Incretin analogs and uses thereof | |
| BR112022004401A2 (en) | Type 2 diabetes mellitus treatment | |
| AR125905A1 (en) | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | |
| EA202092017A1 (en) | NEW GLP-1 ANALOGUES | |
| CL2018002677A1 (en) | Pharmaceutical composition comprising a) metformin, b) rosiglitazone or pioglitazone, c) sitagliptin, linagliptin or vildagliptin, and excipients; and its use for the treatment of the development of ehna, insulin resistance syndrome and type 2 diabetes mellitus, sop. |